PLX PHARMA, INC.

Basic Information

8285 EL RIO
HOUSTON, TX, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 140243572
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Aspirin-PC for Chemoprevention of Colorectal Cancer

    Amount: $147,318.00

    DESCRIPTION (provided by applicant): Colorectal cancer is the third leading cause of cancer-related deaths in the U.S. Based on numerous epidemiological studies and recent prospective trials; the use ...

    STTR Phase I 2013 Department of Health and Human Services
  2. GI-Safer Formulation of Indomethacin for use in Preterm Neonates

    Amount: $1,118,398.00

    DESCRIPTION (provided by applicant): This application is for a SBIR Phase II grant. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, per ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. GI-Safer Formulation of Indomethacin for use in Preterm Neonates

    Amount: $157,934.00

    DESCRIPTION (provided by applicant): This application is a Phase I SBIR grant application. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammati ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Related

    Amount: $745,708.00

    DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by jo ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Relat

    Amount: $263,605.00

    DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by jo ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

    Amount: $729,991.00

    We have developed a novel class of phosphatidylcholine (PC)-associated nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation and pain with reduced GI side-effects. In Phase I studies usin ...

    SBIR Phase II 2008 ArmyDepartment of DefenseDepartment of Defense
  7. Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS

    Amount: $1,533,011.00

    DESCRIPTION (provided by applicant): In this Competing Continuation of our STTR Phase II grant, we propose to build upon the considerable progress made during the previous two funding cycles in our ef ...

    STTR Phase II 2007 Department of Health and Human Services
  8. PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

    Amount: $69,997.00

    Contrasting in vitro and in vivo systems will be used to evaluate the anti-inflammatory/analgesic activity and side-effects of a family of phosphatidylcholine (PC) - associated NSAIDs. Previous studie ...

    SBIR Phase I 2007 ArmyDepartment of DefenseDepartment of Defense

Agency Micro-sites

US Flag An Official Website of the United States Government